- Home
- CCD vs IRWD Comparison
CCD vs IRWD Comparison
Compare CCD & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCD | IRWD |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 629.2M | 526.7M |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | CCD | IRWD |
|---|---|---|
| Price | $23.19 | $3.56 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.94 |
| AVG Volume (30 Days) | 105.6K | ★ 2.3M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ N/A | $24.13 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $19.17 | $0.55 |
| 52 Week High | $23.40 | $5.78 |
Technical Indicators
Market Signals| Indicator | CCD | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 63.53 | 52.13 |
| Support Level | $20.30 | $3.07 |
| Resistance Level | N/A | $3.92 |
| Average True Range (ATR) | 0.63 | 0.21 |
| MACD | 0.25 | 0.07 |
| Stochastic Oscillator | 94.57 | 63.89 |
Price Performance
Historical ComparisonAbout CCD Calamos Dynamic Convertible & Income Fund
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.